The Main Board of the Hong Kong Stock Exchange recently welcomed a notable innovative pharmaceutical company—Hangzhou Highlights Pharmaceutical Co., Ltd. (referred to as Highlights Pharmaceutical), with China International Capital Corporation Limited and CMB International acting as its joint sponsors. Against the backdrop of an increasingly competitive domestic JAK inhibitor landscape, Highlights Pharmaceutical has carved out its own path. Leveraging the unique advantages of its dual-target inhibitors—high selectivity and high brain penetrance—it has become one of the few domestic innovative pharmaceutical firms simultaneously focusing on both autoimmune/inflammatory diseases and central nervous system disorders. Similar to many pre-revenue, pre-profit biotech companies, Highlights Pharmaceutical has no approved products on the market yet, with its most advanced candidates in Phase III clinical trials. This IPO is driven by tight cash reserves and the pressure from a RMB 1.2 billion valuation adjustment agreement. Public information shows that Highlights Pharmaceutical has completed six rounds of financing, raising a total of approximately RMB 662 million. Its post-money valuation after the latest round was about RMB 2.462 billion. Its shareholder list includes several well-known investment institutions such as Hankang Capital, AstraZeneca-CICC, Kaitai Capital, Dr. Tan Fenlai, Yifeng Capital, Zeyue Venture Capital, Kangjun Capital, AIHC Capital, Huajin Capital, Infinity Capital, and Hillhouse Capital. Holding two scarce core assets, can this IPO attract investor interest? What are the highlights of its pipeline across two hot therapeutic areas?
Focusing on Two Major Hot Therapeutic Areas
The autoimmune diseases and neurodegenerative diseases that Highlights Pharmaceutical focuses on both possess significant market potential. Autoimmune diseases encompass various common conditions such as rheumatoid arthritis, ankylosing spondylitis, and atopic dermatitis, featuring a large patient base and long treatment cycles, making it the world's second-largest pharmaceutical market after oncology. Data indicates that the global autoimmune drug market grew from $116.9 billion in 2019 to $143.1 billion in 2024 and is projected to further expand to $179.5 billion by 2028. Represented by Alzheimer's disease and Parkinson's disease, neurodegenerative diseases are a group of highly heterogeneous neurological disorders. Their core pathological feature is the progressive loss of neurons in the central or peripheral nervous system, severely impairing patients' memory, cognition, behavior, sensory functions, and motor control. Due to the extremely complex pathogenesis and the natural barrier of the blood-brain barrier, the development of new drugs for neurological diseases is characterized by exceptionally long cycles and high failure rates.
Reportedly, the number of patients with Alzheimer's disease and other dementias in China is close to 17 million, and Parkinson's disease patients exceed 5 million, representing a growing and substantial healthcare burden. The related global market size reached $61 billion in 2025 and is expected to increase to $114.1 billion by 2035, driven by trends like population aging.
Highlights Pharmaceutical's R&D pipeline comprises seven self-developed small-molecule drug candidates, with four in clinical stages and three in preclinical stages. Among them, the most significant differentiating highlight is its TYK2/JAK1 dual-target inhibitor. JAK is an important family of non-receptor tyrosine kinases. JAK1 plays a central role in systemic inflammatory responses, immune responses, and neural development, making it a hot target for new drug development in inflammation, cancer, and autoimmune diseases. TYK2 primarily affects immune-related signaling, mediating only specific cytokines like IL-12 and type I interferon, and promoting the production of inflammatory cytokines such as IL-23, with minimal interference on others, thus offering higher drug safety potential.
Currently, most kinase inhibitors (including all approved or in-development JAK inhibitors) contain a typical hydrogen-bond donor. Through innovative removal of this donor, Highlights Pharmaceutical successfully developed kinase inhibitors with both higher selectivity and blood-brain barrier penetration capability. This combination of dual characteristics is a first among existing JAK inhibitors. This technological breakthrough allows the company to achieve higher safety within the JAK inhibitor class and effectively address the long-standing challenge of blood-brain barrier penetration in treating neurodegenerative diseases.
In the autoimmune field, the company's core product, TLL-018 (Ginoxitinib), is a selective TYK2/JAK1 inhibitor. It is currently conducting two Phase III registration trials in China for chronic spontaneous urticaria (CSU) and rheumatoid arthritis (RA). HL-300 is a potent, skin-restricted TYK2/JAK1/JAK2 inhibitor being developed as a topical treatment for mild-to-moderate atopic dermatitis (AD).
In the neurodegenerative disease field, the core product TLL-041/BHV-8000 is a brain-penetrant, selective TYK2/JAK1 inhibitor for treating neuroinflammatory diseases including Parkinson's disease and Alzheimer's disease. Additionally, the rest of the company's pipeline includes candidates like HL-400 (a brain-penetrant NLRP3 inhibitor for CNS disease treatment) and HL-500 (an LRRK2 inhibitor for Parkinson's disease treatment).
Differentiating Dual-Target Advantage: A Path Through the Crowded Field?
The competition in the domestic JAK inhibitor field is intensifying. First-generation non-selective products can inhibit multiple targets like JAK1, JAK2, JAK3, and TYK2 simultaneously. While effective, they easily interfere with normal immune function, causing adverse reactions such as infections, anemia, and dyslipidemia. Consequently, they carry FDA black box warnings and have limited clinical use. Second-generation high-selectivity inhibitors can precisely target specific subtypes, reducing impact on other cytokine functions while inhibiting disease-related signaling pathways, significantly improving safety.
However, despite the safety advantages of second-generation products, several high-selectivity JAK inhibitors are already approved in China, with over ten more in clinical stages, indicating the crowded nature of the field.
Highlights Pharmaceutical's core product, TLL-018, is globally the only highly selective TYK2/JAK1 inhibitor, making it a scarce asset, and its development progress is among the global front-runners. Since 2026, TLL-018's clinical progress has consistently delivered positive signals. In January, the drug achieved positive topline data in its Phase III trial for CSU. The interim analysis met the primary endpoint, showing significant superiority over placebo in the primary efficacy measure and multiple secondary efficacy measures, with good safety and tolerability. In April, the primary efficacy analysis for TLL-018 in treating RA was completed, also meeting the primary and all secondary endpoints. It demonstrated superior efficacy to tofacitinib across indicators including the proportion of patients achieving ACR50, ACR20/70, DAS28≤3.2, and DAS28<2.6 at 24 weeks.
Based on these positive data, on June 24, 2026, TLL-018 tablets were proposed for inclusion in the Breakthrough Therapy Designation program for treating rheumatoid arthritis.
Regarding future timelines, Highlights Pharmaceutical plans to submit a New Drug Application for the RA indication in China before the end of 2026, potentially becoming one of the first domestically developed JAK inhibitors to be approved. Simultaneously, the company expects to file a marketing application for the CSU indication in the first quarter of 2027, potentially becoming the world's first JAK inhibitor approved for treating CSU.
Furthermore, for moderate-to-severe atopic dermatitis, the company plans to directly initiate a Phase II/III registration trial in China in the second quarter of 2026, having obtained IND approval in May 2026. Expansion into systemic lupus erythematosus is also planned, with its IND application approved in August 2023.
Currently, the global market for JAK1/TYK2 dual-target inhibitors is essentially blank, with most related pipelines in early clinical stages. In this context, TLL-018 has established a certain leading advantage and could seize market opportunities. However, it is important to note that TLL-018 has so far only completed comparative studies with the first-generation JAK inhibitor tofacitinib. Head-to-head clinical trials against other JAK inhibitors have not yet been conducted. Its overall competitive advantage, long-term efficacy, safety, and final market positioning compared to existing standard therapies still require further validation and assessment through subsequent clinical practice and studies.
Clinical data for Highlights Pharmaceutical's other core product targeting neurodegenerative diseases, TLL-041, also shows promising performance. It has become the world's first and only brain-penetrant selective TYK2/JAK1 inhibitor, possessing the triple unique advantages of high brain penetrance, high selectivity, and biomarker mechanism validation. Clinical studies show that kinase profiling analysis across 358 human kinases indicates TLL-041's selectivity for TYK2 and JAK1 is over 20 times higher than for JAK2 and JAK3, with minimal off-target activity. This differentiated safety profile effectively avoids the hematological and immunosuppressive risks associated with broad JAK inhibition.
Preclinical studies confirmed significant drug concentrations in brain tissue and cerebrospinal fluid after oral administration, and dose-dependent neuroprotective effects were observed in a dsRNA-induced neuroinflammation human neuronal model. This also addresses the historical challenge of difficulty in directly measuring drug concentration in brain tissue and assessing the correlation between efficacy and clinical endpoints.
Regarding commercial rights, TLL-041's ex-China rights have been licensed to Biohaven. According to the collaboration agreement, Highlights Pharmaceutical is eligible for a $10 million upfront payment, 721,136 shares of Biohaven common stock, up to $950 million in clinical and commercial milestone payments, plus tiered sales royalties post-commercialization. In August 2025, the company received the first milestone payment for this project, amounting to $15 million. Currently, Biohaven has initiated a global Phase II/III registration study for early Parkinson's disease, marking the first known application of a TYK2/JAK1 inhibitor in neurodegenerative diseases. In China, Highlights Pharmaceutical completed the pharmacokinetic bridging study for TLL-041 in March 2026. The next step involves participating in Biohaven's global registration study program for Parkinson's disease. The company submitted the clinical study protocol for this registration trial to the National Medical Products Administration in December 2025 and is awaiting feedback.
Financial Status and Funding Needs
According to the prospectus, for the years 2024, 2025, and the three months ended March 31, 2026, Highlights Pharmaceutical recorded losses of approximately RMB 226 million, RMB 312 million, and RMB 73.121 million, respectively. R&D expenses for 2024 and 2025 were RMB 127 million and RMB 151 million, respectively. The company also faces significant cash flow pressure. As of the end of 2025, its cash and cash equivalents balance was only RMB 256 million, highlighting the urgency of the IPO financing.
Furthermore, past financing rounds included investor redemption rights. If the company fails to complete a qualified listing by the end of 2027, investors have the right to demand redemption at the original investment principal plus a 20% annual interest rate. As of the end of March 2026, the carrying amount of this financial instrument had reached RMB 1.206 billion, fully classified as current liabilities. If the listing process is delayed, the massive pressure from the valuation adjustment agreement could threaten the company's ability to continue as a going concern.
Conclusion
Overall, Highlights Pharmaceutical's scarce pipeline is quite noteworthy. TLL-018's past clinical data is positive, and it has already secured its first milestone payment, indicating its potential commercial value has gained market recognition. If TLL-018 succeeds in subsequent head-to-head trials, or if TLL-041 performs well in future Parkinson's disease clinical studies, both could command considerable valuation premiums, warranting continued market attention.